Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must give their written informed consent before any procedure related to the study is performed; therefore, it must be given at the selection visit. The patient must be informed that he has the right to withdraw from the study at any time, without any kind of prejudice.~* Patients with renal clear cell carcinoma (RCC), unresectable and/or metastatic, histologically or cytologically documented (excluding the less common subtypes).~* Patients must not be candidates for any immunotherapeutic treatment, according to the response predictive factors, or must be intolerant to immunotherapeutic treatment.~* Patients classified as having median or low risk, according to Motzer's scoring.~* Patients (men or women) with ages equal or superior to 18 years old.~* ECOG ≤ 1.~* Assessable or measurable disease.~* Patients with adequate haematological function, defined as:~  * Neutrophils ≥ 1.5 x 10\^9/L~ * Blood platelets ≥ 100 x 10\^9/L~ * Haemoglobin ≥ 10 g/dl~* Patients with adequate hepatic, renal, medullar and coagulation function, according to the following criteria:~  * Total bilirubin \< 1.5 times the superior limit of normality~ * ALT and AST \< 2.5 times the superior limit of normality (\< 5 times the superior limit of normality in case of liver failure due to cancer)~ * Amylase and lipase \< 1.5 times the superior limit of normality~ * Serum creatinine \< 2 times the superior limit of normality~ * TP or INR and TTP \< 1.5 times the superior limit of normality. If patient is receiving anticoagulants, strict monitoring will be carried out, with evaluations on a weekly basis, at least, until the INR is stable, referring to a determination previous to dose administration, according to local standard care.~* Patients with a life expectancy superior to 12 weeks, at least.~* Patients may have received radiotherapy; however, this must not be the only target lesion.~* Patients from both sexes must use adequate contraceptive methods (oral or injectable contraceptives, intrauterine device, condom, sterilization) whilst participating in the protocol. After the retreat of treatment with BAY 43-9006, the contraceptive methods must be used for 4 weeks in women and for 3 months in men.~* Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions while on study~Exclusion Criteria:~* Patients who do not give their written informed consent to participate in the study.~* Patients with less common RCC subtypes, such as pure papillary cell tumours, Bellini carcinoma, medullary carcinoma or the oncocytic chromophobes and sarcomatoid variants, will be excluded from the study.~* Patients that have received previous treatment with chemotherapy or that had tumours that evolved during or after immunotherapy treatment.~* Patients that, due to their characteristics, may obtain a potential benefit from immunotherapy treatment.~* Patients that have received previous anti-angiogenic treatment.~* High-risk patients according to Motzer's classification.~* Concomitant treatment with another chemotherapy or immunotherapy.~* Arterial uncontrolled hypertension, which is defined as a systolic arterial pressure value \> 150 mmHg or diastolic arterial pressure value \> 90 mmHg, despite adequate medical treatment.~* Patients with a primary cancer diagnosis different from RCC, except in situ cervical carcinoma, baseline cellular carcinomas or superficial bladder tumours, prostate cancer pT1 gleason \< 6 or other malign tumours which have received curative treatment \> 5 years previous to the inclusion in this study.~* Cardiac arrhythmia antecedents, that require treatment with anti-arrhythmics (except for beta-blockers or digoxin), symptomatic coronary disease or ischemia (myocardial infarction in the previous 6 months) or congestive cardiac insufficiency \> New York Heart Association (NYHA) class II~* Patients with active bacterial or fungal infectious processes, which are considered severe from the clinical point of view (≥ Common Terminology Criteria from the National Cancer Institute \[CTC from NCI\] grade 2, version 3)~* Patients that present previously known positive serology for HIV or chronic hepatitis B or C.~* Antecedents of organ allograft.~* Meningeal carcinomatosis or symptomatic uncontrolled cerebral disease.~* Patients with epileptic disorders that require medication (such as antiepileptics).~* All unstable conditions that could put the patient's security and/or his study accomplishment in danger.~* Abuse of substances, clinical conditions, psychological or social, that may interfere with the patient's participation in the study or with the evaluation of the study's results.~* Patients that present any contraindication or allergy to the study's investigational product.~* Patients that are participating or that have participated in any clinical trial in the 4 weeks previous to inclusion.~* Pregnant or breastfeeding women. Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication. Both men and women included in the study must use an adequate contraceptive method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).